Literature DB >> 15760733

Spectrofluorimetric study of eflucimibe-gamma-cyclodextrin inclusion complex.

Nathalie Mesplet1, Philippe Morin, Jean-Paul Ribet.   

Abstract

Eflucimibe, a novel and highly potent acyl-coenzyme A cholesterol O-acyl-transferase (ACAT) inhibitor, is sparingly soluble in aqueous media and exhibits a very weak natural fluorescence. However, when increasing concentrations of gamma-cyclodextrin (gamma-CD) are added, an increase in the fluorescence signal is observed, attesting the formation of a non-covalent inclusion complex between eflucimibe and the gamma-CD. In this work, the stoichiometry of the complex and the corresponding association constant have been determined from fluorescence data by Benesi-Hildebrand's method (double reciprocal plots). As a result, a 1:1 stoichiometric ratio and a 20 M(-1) formation constant were obtained. This apparent formation constant was determined in water containing 10% methanol, which was needed to improve 'aqueous' solubility of the drug in a CD-free medium. Owing to the extreme hydrophobicity of eflucimibe, these results provide valuable information for pharmaceutical formulation studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15760733     DOI: 10.1016/j.ejpb.2004.09.011

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  1 in total

1.  Facile method to incorporate high-affinity ACAT/SOAT1 inhibitor F12511 into stealth liposome-based nanoparticle and demonstration of its efficacy in blocking cholesteryl ester biosynthesis without overt toxicity in neuronal cell culture.

Authors:  Adrianna L De La Torre; Caleb Smith; Joseph Granger; Faith L Anderson; Taylor C Harned; Matthew C Havrda; Catherine C Y Chang; Ta-Yuan Chang
Journal:  J Neurosci Methods       Date:  2021-12-07       Impact factor: 2.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.